APO-IMIPRAMINE TABLETS 50 MG

What is APO-IMIPRAMINE TABLETS?

APO-IMIPRAMINE TABLETS 50 MG contains IMIPRAMINE HYDROCHLORIDE : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 00326852, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Jan-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is APO-IMIPRAMINE TABLETS used for?

The relief of symptoms of depressive illness. As with other tricyclic antidepressants, APO-IMIPRAMINE TABLETS may precipitate hypomanic episodes in patients with bipolar depression. These drugs are not indicated in mild depressive states and depressive reactions.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

How is it administered?

Adult patients: The recommended initial dosage is 25 mg three times/day. This should be increased gradually as required and tolerated, up to 150 mg/day. Dosage over 200 mg/day is not recommended for outpatients. Severely ill or hospitalized patients may require up to 300 mg/day. Elderly patients: The recommended initial dosage is 30 to 40 mg/day. Increase the dose by 10 mg/day to a maximum of 100 mg/day. Pediatric patients (<18 years of age): Health Canada has not authorized an indication for pediatric use. Maintenance: In suitable subjects, the maintenance dose may be administered in a single dose before bedtime. Discontinuation: When discontinuing APO-IMIPRAMINE TABLETS, the dosage should be tapered gradually over several weeks. Administration: APO-IMIPRAMINE TABLETS should be swallowed whole with water. Missed Dose: If a dose is missed, take it as soon as remembered. If it is almost time for the next dose, skip the missed dose and continue the regular dosing schedule. Do not take two doses at the same time.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Store at controlled room temperature (15°C-30°C). Keep out of reach and sight of children. APO-IMIPRAMINE TABLETS should never be disposed of in household trash. Disposal via a pharmacy take back program is recommended.

How is it supplied?

Available in bottles of 100 or 1000 tablets.

Contraindications

APO-IMIPRAMINE TABLETS is contraindicated in: • Patients who are hypersensitive to imipramine hydrochloride or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. • Patients with known or suspected hypersensitivity to tricyclic antidepressants (TCA) belonging to the dibenzazepine group. • In conjunction with, or within 14 days before or after treatment with monoamine oxidase inhibitors (MAOIs). • During the acute recovery phase following a myocardial infarction and in the presence of acute congestive heart failure. • Patients with narrow angle glaucoma, as the condition may be aggravated due to the atropine-like effects of the drug.

Warnings and precautions

Extreme caution should be used when APO-IMIPRAMINE TABLETS is given in the following situations: • Cases of QT interval prolongation, cardiac arrhythmia and severe hypotension have been reported. Unexpected death has occurred in patients with cardiovascular disorders. Myocardial infarction and stroke have been reported. Caution is advised in patients with a history of cardiovascular disorders (e.g., significant bradycardia, myocardial infarction, congestive or uncompensated heart failure), conduction abnormalities or patients with risk factors for QT interval prolongation, such as concomitant use of QT-prolonging drugs. • Unmasking of Brugada syndrome has been reported with tricyclic antidepressants. APO-IMIPRAMINE TABLETS should be avoided in patients with Brugada syndrome or those suspected of having Brugada syndrome. • In patients with a history of urinary retention or prostatic hypertrophy, or in patients with increased intraocular pressure or narrow angle glaucoma, because of the anticholinergic properties. • In patients with thyroid disease or those taking thyroid medication, due to the possibility of cardiovascular toxicity, including arrhythmias. • In patients with a history of a seizure disorder, because APO-IMIPRAMINE TABLETS has been shown to lower the seizure threshold. • Clinical Worsening and Suicide Risk: Increased risk of self-harm, harm to others, suicidal thinking and behavior with antidepressant use. Closely monitor all antidepressant-treated patients for clinical worsening and for emergence of agitation-type and/or suicidal thoughts and behaviors.

What can be used instead?

Other Canadian products sharing ATC code N06AA02 IMIPRAMINE. 8 of 32 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

Who else supplies IMIPRAMINE worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. IMIPRAMINE appears in 17 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.